

Daniilo Perrotti, MD, Ph.D.

Assistant Professor
Human Cancer Genetics
The Ohio State University

Address

Human Cancer Genetics Program
Department of Molecular Virology, Immunology and Medical Genetics
College of Medicine and Public Health
The Ohio State University Comprehensive Cancer Center
The Innovation Centre
2001 Polaris Parkway Room 205
Columbus OH, 43240 USA
Tel.: (614) 293-5739
Fax: (614) 293-5952
E-mail: danilo.perrotti@osumc.edu

Education

- 1984: Bachelor of Science (B.S.) degree Liceo Scientifico Statale "F. D'Assisi" Rome Italy.
1991: Medical Doctor (M.D.) degree University of Rome "La Sapienza" Italy. Graduated with 110/110 summa cum laude, on the basis of public defense of thesis entitled: "Metastatic phenotype: Growth factor dependence and Integrin expression"
1991: Italian Medical Board Examination.
1997: Ph.D. in Biotechnology (Ph.D.). University of L'Aquila, Italy. Public defense of a dissertation entitled: "Transcriptional regulation of hematopoietic cell proliferation and differentiation".

Professional experience :

- 1985-90 Pre-graduating training. (voluntary student). Dep. of Human Biopathology - Experimental Medicine -University of Rome "La Sapienza" and Molecular Oncogenesis Lab. - Regina Elena Cancer Institute of Rome, Italy.
1990-91 Research Assistant, Molecular Oncogenesis Lab., Regina Elena Cancer Institute of Rome, Italy.
1992 Physician Officer, Italian Military Air Force Academy.
1992 Visiting Scientist, International Institute of Genetic and Biophysics (IIGB-C.N.R.) Naples, Italy.
1993- 97 Ph.D. Student in Biotechnology, Regina Elena Cancer Institute, Rome, Italy.
1993-97 Postdoctoral Researcher, Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, PA.
1998-2002 Research Instructor, Kimmel Cancer Institute, Thomas Jefferson University- Philadelphia, PA
9/02-3/03 Research Assistant Professor, Kimmel Cancer Institute, Thomas Jefferson University- Philadelphia, PA
4/2003- Assistant Professor (tenure-track), Human Cancer Genetics Program, Dept. Molecular Virology, Immunology and Medical Genetics. Ohio State University, Columbus, OH.
4/2003- Member of the Comprehensive Cancer Center (Molecular Biology and Cancer Genetics Program), The Ohio State University, Columbus OH 43210.

Honors/Awards:

- 1990-91 Fellowship from the Italian Ministry of Health.
1992-95 Fellowship from the Italian Ministry of Universities and Scientific Research.

1994	Individual Award "P. Bolognesi" for young investigator in Cancer Research. Board of Physicians of Rome- Italy.
1997-99	Fellowship from the American Italian Foundation for Cancer Research. New York (NY).
2002	Elsa U. Pardee Foundation for Cancer Research Grant Award
2003	Lauri Strauss Leukemia Research Foundation Grant Award
2005	OSUCCC Research Enhancement and Assistance Program (REAP) Award
2006	OSUCCC Research Enhancement and Assistance Program (REAP) Award
2007	Career Development Award, Scholar - Leukemia and Lymphoma Society of America.

Professional Activities:

Instructor/Teaching

1989	Instructor "Advanced Course in Molecular Pathology and Biotechnology", organized by Ares Serono Symposia, University of Rome "La Sapienza" and Regina Elena Cancer Institute.
1994 –2003.	MD and Ph.D. Students Research Trainer. Thomas Jefferson University- Philadelphia, PA.
1997 -2003	Instructor to postdoctoral fellows and graduate students (Kimmel Cancer Center, Dept. Microbiology and Immunology, Thomas Jefferson University, Philadelphia PA)
2004-present	Graduate Faculty Integrated Biomedical Graduate Program (IBGP), The Ohio State University Medical College.
2006-present	Graduate Faculty Molecular, Cellular and Developmental Biology (MCDB) Integrated Graduate Program; The Ohio State University.

Grant Reviewer

2002-2007	External Grant reviewer for the AIRC (Italian Association for Cancer Research).
2003	Technical Grant reviewer for Biotechnology Greenhouse Corporation of Southeastern Pennsylvania, BioAdvance Funds, Philadelphia, PA.
2004	DOD-CMLRP Exploration-Hypothesis Development Award, CML Research Program- Congressional directed Medical Research program, US Dept of Defense.
2004	DOD-CMLRP Therapeutic Developmental Award, CML Research Program- Congressional directed Medical Research program, US Dept of Defense.
2004	American Cancer Society (ACS) Seed Grants 2004-05
2005	T32 Medical Oncology NCI training grants
2005	<i>Ad hoc</i> Member, Special Emphasis Panel (SEP) NIH-NHLBI. Myelodysplastic Syndrome and Myeloproliferative Disorders
2005	DOD-CMLRP Hypothesis and Therapeutic Developmental Awards, CML Research Program- Congressional directed Medical Research program, US Dept of Defense.
2005	External Reviewer for the Dutch Cancer Society
2006	NCI's P01 Cluster Review Panel Clinical and Molecular Oncology
2007	External Reviewer for the Erwin Schroedinger Program-application received by the Austrian Science Fund (FWF).

Academic Committees and Intramural Activities

2004-07	Alternate Member, Medical Scientist Program (MSP) Steering Committee
2004	Member, MVIMG/HCG Seminar Committee
2004	Session Chair, MVIMG Research Colloquium, May 8 th 2004
2005-07	Poster Judge, Graduate and Postgraduate Research Day, OSU Medical College.
2005-07	Chair, MVIMG Seminar Committee
2005	Committee Member and Honor Thesis advisor for undergraduate students (Richard J. and Martha D. Denman Undergraduate Research Forum Award)
2005-07	1 st year and/or dissertation Committee Member/Advisor for IBGP graduate students
2005-07	Graduate Faculty Representative for candidacy and final exams

Extramural Committees and Activities

- 2004-07 Council Member, Gerson Lehrman Group's Council of Healthcare Advisors
 2007 Abstract Reviewer "Chronic Myelogenous Leukemia Section, 49th American Society of Hematology (ASH) Annual Meeting.
 2007 Reviewer for Hematology 2007, American Society of Hematology Education Program Book.
 2007 Chair, Session II, Targeted Drugs in Chronic Myeloid Leukemia. Vienna, October 26-28, 2007.

Editorial Activity:Editorial Board Member:

2004-present Permanent Reviewer, Medical Science Monitor Journal

2007-present Associate Editor, Cancer Research

Ad hoc Reviewer for:

- American Journal of Hematology
- American Journal of Pathology
- Biologics: targets and therapy
- Blood
- Cancer Research
- Cancer Therapy
- Cell Death and Differentiation
- Clinical Cancer Research
- Experimental Hematology
- European Journal of Immunology
- European Journal of Cancer
- Gene
- Hematologica
- Journal of Clinical Oncology
- Journal of Experimental Medicine
- Leukemia
- Molecular and Cellular Biology
- Molecular Cancer Therapeutics
- Molecular Carcinogenesis
- Nature Genetics
- Nature Reviews of Cancer
- Nucleic Acid Research
- Oncogene
- Theoretical Biology and Medical Modelling

Support:ACTIVE:

- | | |
|--|-----------|
| 1. 1R01 CA095512-01 (PI: Perrotti) 08/01/03-10/31/07
NIH-NCI
Role of RNA binding protein in BCR/ABL leukemogenesis | \$980,876 |
| 2. DOD-CML NIA –CM064051 (PI: Perrotti) 04/01/07-03/31/10
CMLRP US Dept. Army
Restoration of PP2A tumor suppressor activity as therapeutic strategy for CML-BC.
Score: 1.2±0.11 | \$675,000 |
| 3. American-Italian Cancer Foundation (PI: Neviani) 07/01/2006-06/30/2008
Pharmacologic activation of PP2A as a potential therapy for imatinib sensitive and resistant Ph1 leukemia.
Role: Mentor/Supervisor | \$70,000 |
| 4. Career Development award (Scholar) (PI: Perrotti) 07/01/07-06/30/2012
Leukemia And Lymphoma Society | \$550,000 |

Activating Phosphatases as therapeutic strategy for leukemias characterized by activated oncogenic tyrosine kinases: Role of PP2A in Chronic Myelogenous Leukemia

ENDED

- | | |
|--|-----------|
| 1. DOD-CML (PI: Perrotti) 7/1/03-10/31/06
Department of the Army
Effect of BCR/ABL oncoprotein on mRNA translation: Possible mechanisms responsible for CML disease progression. | \$750,000 |
| 2. Elsa U. Pardee Foundation Grant (PI: Perrotti) 06/01/02-12/31/03
Translational Regulation by the p210 BCR/ABL oncoprotein | \$86,381 |
| 3. Lauri Strauss Leukemia Research Grant (PI: Perrotti) 04/01/03-3/31/04
Role of the BCR/ABL oncogene in Suppression of neutrophilic differentiation | \$35,000 |

PENDING

- | | |
|---|-------------|
| 1. Competitive Renewal 2RO1 CA095512-01 (PI: Perrotti) 08/01/07-7/31/12
NIH-NCI
Role of RNA binding protein in BCR/ABL leukemogenesis
Priority score:155
Percentile 17.2 | \$1,500,000 |
| 2. 1T32 CA124364-01 (Director: Croce, CM) 12/1/06 - 11/30/11
NIH/NCI
Predoctoral and Postdoctoral Training Program in Molecular Oncology
Role: Co-Director
<i>Priority Score: 222</i>
<i>A Revised version submitted on January 25th 2007</i> | \$2,565,899 |
| 3. NIH-NCI (PI: Gao, Jian-Xin) 07/01/2006-06/30/2011
The significance of mli in cancer stem cell development
Role: Co-Investigator (5% effort) | \$1,868,750 |

Membership in Professional Societies:

- | | |
|--|---------------|
| 1. 1996-present American Association for Cancer Research (AACR) | Active Member |
| 2. 1997-present American Society for Cell Biology (ASCB) | Member |
| 3. 1996-present American Association for the Advancement of Science (AAAS) | Member |
| 4. 2000-present American Society of Hematology (ASH) | Member |
| 5. 2004-present Cancer and Leukemia Group B (CALGB) | Member |

Lectures:

1. Invited speaker at Regina Elena Cancer Institute, Rome Italy. May 25th, 1999. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
2. Invited speaker for "Special Seminar" at Harvard Institute of Medicine, Boston MA. April 26, 2000. The BCR/ABL-downstream effector TLS/FUS as Regulator of Normal and Leukemic Hematopoiesis.

3. Invited speaker at Brown Cancer Center, University of Louisville, Louisville, KY. July 23, 2002. Shuttling hnRNPs and CML: Altered mRNA metabolism as a consequence of BCR/ABL leukemogenic activity”
4. Invited Speaker for The Kimmel Cancer Center Annual Retreat, Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia PA 2002. "Role of RNA binding protein in the regulation of BCR/ABL leukemogenesis".
5. Invited speaker at Div. Human Cancer Genetics, OSU Comprehensive Cancer Center, Ohio State University, Columbus, OH. Sept. 9, 2002. Altered mRNA translation as a consequence of BCR/ABL leukemogenic activity”
6. Invited Speaker at NICHD, NIH, Bethesda, MD. December 12,2002. “Altered mRNA translation as consequence of BCR/ABL leukemogenic activity”.
7. Invited Speaker Regina Elena Cancer Institute, Rome Italy. Dec. 20, 2002. “Genomics, Ribonomics and Proteomics: An Integrated Three Level Study To Characterize the Effect of BCR/ABL on mRNA Metabolism”
8. Invited Speaker Blood Research Institute, Medical College, University of Wisconsin, Milwaukee, WI. Nov. 11th, 2003. The oncoprotein BCR/ABL as regulator of mRNA translation: mechanisms of CML disease progression
9. Invited Speaker, RNA Group meeting, Dept. of Pathology. The Ohio State University. Columbus OH 43210. Jan. 23rd 2004 Altered mRNA metabolism in Chronic myelogenous leukemia
10. Invited Speaker, Dept. Molecular Virology Immunology and Medical Genetics. The Ohio State University, Columbus OH 43210. January 28th , 2004. New Insights in the biology of Blast crisis Chronic Myelogenous Leukemia.
11. Invited Speaker, Experimental Therapeutics Program , Phase 1 trial meeting. The Ohio State University, Columbus OH 43210. September 22nd , 2004. Re-SET-ting PP2A activity in blast crisis CML.
12. Invited Speaker, Molecular Biology and Cancer Genetics Program The Ohio State University, Columbus OH 43210. November 3rd, 2004. BCR/ABL and PP2A: The Yin and Yang of CML
13. Invited Speaker, *The Feist-Weiller Cancer Center-Hematology/Oncology at Louisiana State University Health Sciences Center in Shreveport, LA.* November 16th , 2004. Looking for the Yin and Yang of CML.
14. Invited Speaker, *Maisonneuve-Rosemont Hospital Research Center, Department of Medicine, Universite de Montreal, Montreal, QC, Canada.* May 20th, 2005. Activation of PP2A overcomes BCR/ABL leukemogenic potential in blast crisis CML.
15. Invited Speaker, Third ESH International Conference on CHRONIC MYELOID LEUKAEMIA IN THE 21st CENTURY. Chairs: A. Carella, J. Goldman. Activating PP2A to overcome BCR/ABL leukemogenic potential in blast crisis and imatinib-resistant CML. Genoa, Italy November 2005.
16. Invited Speaker, Workshop on Myeloid Development. Section: Myeloid Malignancies. Chair: Gary Gilliland. ReSETting PP2A activity to overcome BCR/ABL leukemogenic potential in blast crisis CML. December 9th 2005, Atlanta GA.
17. Invited Speaker, IBGP 797 Module 8. Title: PP2A and BCR/ABL: The Yin-Yang of Chronic Myelogenous Leukemia. The Ohio state University Medical Ctr., Columbus OH. Jan. 19th, 2006.
18. Invited Speaker, The Pharmacology Seminar Series. Dept. of Pharmacology and College of Pharmacy. The Ohio State University. Feb. 17th, 2006. Pharmacologic activation of PP2A tumor suppressor antagonizes BCR/ABL leukemogenesis.
19. Invited Speaker, Hematology Grand Rounds, University of Texas MD Anderson Cancer Center. Houston TX. April 12th, 2006. Resetting PP2A tumor suppressor activity overcomes BCR/ABL leukemogenic potential in blast crisis and imatinib-resistant CML.

20. Invited Speaker, Kimmel Cancer Center Special Seminars, Thomas Jefferson University, Philadelphia PA. June 22nd, 2006. Pharmacologic resetting of PP2A tumor suppressor antagonizes BCR/ABL leukemogenic potential in blast crisis CML.
21. Invited Speaker, FASEB Summer Research Conference on "Protein Phosphatases" Title: PP2A and BCR/ABL: The Yin-Yang of Chronic Myelogenous Leukemia. July 15-20th, 2006. Snowmass Village, Colorado.
22. Invited Speaker, University of Colorado Health Science Center, Denver CO. September 5, 2006. Studying mRNA metabolism for discovering alternative cancer therapies: Role of RNA binding proteins in CML disease progression.
23. Invited speaker Experimental Hematology Children Hospital, University of Cincinnati (Cancer Center Special Lecture), Cincinnati, Ohio. Nov. 3rd, 2006. PP2A Activators as a Novel Strategy for Imatinib/Dasatinib-resistant Blast Crisis CML and Ph1 ALL.
24. Invited Speaker Road to a Cure: The CML Investigator's Meeting, Dec. 7-8 Orlando, Florida. CDMRP, US Dept. of The Army – CML Research Program. From RNA binding proteins to therapy: The PP2A activator FTY720 as an alternative treatment for imatinib/dasatinib-resistant and blast crisis CML patients.
25. FTY720, A New and Alternative Strategy for Treating Blast Crisis CML and Ph¹ ALL Patients. 48th Annual Meeting American Society of Hematology. Orlando FL Dec. 9-12 2006. Acute Lymphoblastic Leukemia Simultaneous Session
26. Invited Speaker 1st Global CML Workshop – The Future, Bermuda, Dec. 14-17, 2006 (Session: Resistance to Imatinib) Loss of the PP2A tumor suppressor, an essential step in blastic transformation and an ideal target for an alternative therapy of blast crisis and imatinib-resistant CML.
27. Invited Speaker 1st Global CML Workshop – The Future, Bermuda, Dec. 14-17, 2006 (Session: Mechanism of blastic transformation) High BCR/ABL Levels: An absolute requirement for the phenotype of blast crisis CML cells."
28. Invited Speaker, Department of Biochemistry and Molecular Biology, Indiana University School of Medicine. Indianapolis IN (March 12th 2007) Pharmacologic activation of PP2A, a Novel and Alternative Strategy for Treating imatinib- and dasatinib-resistant Ph1 Leukemias.
29. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. 98th Annual Meeting American Association for Cancer Research. April 14-18, 2007. Los Angeles CA. Experimental Therapeutic Oral presentation.
30. Invited Speaker, City of Hope National Medical Center, Department of Hematopoietic Stem Cell and Leukemia Research. (April 25th 2007) Activating Phosphatases as an Alternative treatment for Ph1(+) Leukemias. Invited Speaker, City of Hope National Medical Center, Department of Hematopoietic Stem Cell and Leukemia Research.
31. Speaker, Dept. Molecular Virology Immunology and Medical Genetics. The Ohio State University, Columbus OH 43210. May 7th, 2007. "From RNA binding proteins to Cancer Therapy: BCR/ABL shows the way.

Upcoming

32. Invited Speaker, The ESH International Meeting on Chronic myeloid leukaemia – biological basis of therapy, Prospects for the 21st Century. Mandelieu, France, 28-30 September 2007

33. Invited Speaker, The European CML Conference, Targets and Targeted Drugs in Chronic Myeloid Leukemia. October 27-29, 2007 Vienna, AU.
34. Invited Speaker, Special Lecture _Interdisciplinary Center for Clinical Research (IZKF), Muenster, Germany. October 29
35. Invited Speaker, 2nd Global CML Workshop – The Future. Puerto Rico, Dec. 12-13, 2007
36. Invited Speaker, University of Michigan Comprehensive Cancer Center, Dept. Internal Medicine (2007)
37. Invited Speaker, FASEB Summer Research Conference on “Protein Phosphatases” July 13-18th, 2008. Snowmass Village, Colorado.
38. Invited Speaker, HMRI Cancer Conference, Pathways to Tailored Therapies. Newcastle, Australia September 10-12, 2008

PATENT:

1. Perrotti D et al.. (PCT/US2006/10882). “Activation of PP2A in the Treatment of Ph1 Leukemias” *Final Patent Filed* March 24th 2006. Application Serial Number: 60/665,091 final application *pending*
2. Byrd J.and Perrotti D.. (PCT/US2007/00046049) “Therapeutic agents for the treatment of lymphoid malignancies” final PCT patent file submitted on June 1st 2007. Patent Pending.

PUBLICATIONS (peer reviewed articles and editor invited reviews):

1. **Perrotti, D.**, L. Cimino, R. Falcioni, G. Tibursi, M.P. Gentileschi, and A. Sacchi. "Metastatic phenotype: growth factor dependence and integrin expression". *Anticancer Res.* (10): 1587-1598, 1990.
2. Cimino L., **D. Perrotti**, R. Falcioni, S.J. Kennel, and A. Sacchi. "Integrin expression on *in vitro* and *in vivo* metastatic variants of Lewis Lung Carcinoma. *Cytotechnology* (5) S: 45-48, 1991.
3. **Perrotti, D.**, L. Cimino, S. Ferrari, and Ada Sacchi. Differential expression of TGF- β 1 gene in 3LL metastatic variants. *Cancer Res.* (51): 5491-5494, 1991.
4. Citro G., **D. Perrotti**, C. Cucco, I. D'Agnano, A. Sacchi, G. Zupi and B. Calabretta. "Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myc antisense oligodeoxynucleotides" *Proc. Natl. Acad. Sci. USA*, (89): 7031-7035, 1992.
5. G.Piaggio, A. Farina, **D. Perrotti**, I. Manni, P. Fuschi, A. Sacchi and C. Gaetano. Structure and growth-dependent regulation of the human cyclin B1 promoter. *Exp. Cell Res.* , 216 (2): 396-402, 1995
6. Skorski T., M. Nieboroska-Skorska, C. Szczylik, P. Kanakaraj, **D. Perrotti**, G. Zon, A. Gewirtz, B. Perussia and B. Calabretta. c-Raf-1 Serine/Threonine Kinase is required in BCR/Abl-dependent and normal Hematopoiesis. *Cancer Res.* 55: 2275-2278, 1995. .
7. **Perrotti,D.**, P. Melotti, T. Skorski, I. Casella, C. Peshle and B. Calabretta. Overexpression of the Zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myc promoter activity. *Mol. Cell. Biol.*, 15 (11): 6075-6087, 1995.

8. **Perrotti, D.**, T. Bellon, R. Trotta, R. Martinez, and B. Calabretta. A cell-proliferation dependent multiprotein complex NC-3A positively regulates the CD34 promoter via a TCATTT-containing element. *Blood*, 88(9): 3336-3348, 1996.
9. Skorski T., M. Nieborowska-Skorska, P. Wlodarski, **D. Perrotti**, R. Martinez, M. A. Wasik, and B. Calabretta. Blastic transformation of p53-deficient bone marrow cells by p210^{bcr/abl} tyrosine kinase. *Proc. Natl. Acad. Sci. USA*, 93: 13137-13142, 1996.
10. Skorski T., M. Nieborowska-Skorska, P. Wlodarski, **D. Perrotti**, G. Hoser, J. Kawiak, M. Majewski, L. Christensen, R. V. Iozzo, and B. Calabretta. Treatment of Philadelphia leukemia in SCID mice by combination of cyclophosphamide and BCR/ABL antisense oligodeoxynucleotides. *J. Natl. Cancer Inst.*, 89 (2): 124-133, 1997.
11. Martinez R., D. Venturelli, **D. Perrotti**, M. L. Veronese, K. Kastury, T. Druck, K. Huebner, and B. Calabretta. Gene structure, promoter activity and chromosomal location of the DR-nm23 gene. *Cancer Res.*, (57): 1180-1187, 1997.
12. Salomoni P., **D. Perrotti**, R. Martinez, C. Franceschi and B. Calabretta. Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb dependent regulation of bcl-2 promoter activity. *Proc. Natl. Acad. Sci. USA*, (94): 3296-3301, 1997.
13. Skorski T., **D. Perrotti**, M. Nieborowska-Skorska, S. Gryaznov and B. Calabretta. Antileukemia effect of c-myc N3'→P5' phosphoroamidate antisense oligonucleotides in vivo. *Proc. Natl. Acad. Sci. USA*, (94), 3966-3971, 1997
14. Cimino L., **D. Perrotti**, R. Falcioni, G. D'Agostino, S.J. Kennel and A. Sacchi. β 4 integrin subunit expression is down-regulated in low metastatic carcinoma variant. *Cancer Detect. Prev.*, (21): 158-166., 1997.
15. Lanza-Jacoby S., N. Sedkova, B. Calabretta H. Phetteplace and **D. Perrotti**. Sepsis-induced regulation of lipoprotein lipase expression in rat adipose tissue and soleus muscle. *J. Lipid Res.* 38 (4): 701-710, 1997.
16. Bellon T *, **D. Perrotti** * and B. Calabretta. Granulocytic differentiation of normal hematopoietic precursor cells induced by the transcription factor PU.1 correlates with negative regulation of the c-myc promoter. *Blood*, 90 (5): 1828-1839, 1997. (*): Equal contribution.
17. Skorski T., A. Bellacosa, M. Nieborowska-Skorska, R. Martinez, M. Majewski, R. Trotta, P. Wlodarski, **D. Perrotti**, T. O. Chan, P.N. Tsichlis, and B. Calabretta. Transformation of hematopoietic cells by BCR/ABL requires activation of PI-3K/Akt- depend pathway. *EMBO J.* 16(20): 6151-6161, 1997.
18. Ratajczak MZ., **Perrotti D.**, Melotti P., Powzaniuk M., Calabretta B., Onodera K., Kregenow D.A., Machalinski B. and Gewirtz A.M. Myb and ets proteins are candidate regulators of c-kit expression in human hematopoietic cells. *Blood*. 91(6): 1934-1946, 1998.
19. **D. Perrotti**[#], Bonatti S., Trotta R., Martinez R., Skorski T., Salomoni P., Grassilli E., Iozzo R.V., Cooper D.R. and B. Calabretta. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. *EMBO J.* 17 (15): 4442-4455, 1998. ([#]): co-corresponding author
20. Iozzo R.V., Chakrani F., **Perrotti D.**, McQuillan D.J., Skorski T., Calabretta B. and I. Eichstetter. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. *Proc Natl Acad Sci USA*, 96(6):3092-3097, 1999.

21. Grassilli E., Salomoni P., **Perrotti D.**, Franceschi C. and B. Calabretta. Resistance to apoptosis in CTLL-2 cells overexpressing B-Myb is associated with B-Myb-dependent bcl-2 induction. *Cancer Res.* 59(10):2451-6, 1999
22. Manzella L., Gualdi R., **Perrotti D.**, Nicolaides N.C., Girlando G., Giuffrida M.A., Messina A. and B. Calabretta. The Interferon Regulatory Factors 1 and 2 bind to a segment of the human c-myc first intron: possible role in the regulation of c-myc expression. *Exp. Cell Res.* 256(1):248-56., 2000
23. Venturelli D., Engelhard A., **Perrotti D.** and B. Calabretta. The nucleoside diphosphate kinase activity of DR-nm23 is not required for inhibition of differentiation and induction of apoptosis in 32Dcl3 myeloid precursor cells. *Exp. Cell Res.*, 257(2): 265-71, 2000.
24. **Perrotti D**[#], Iervolino A., Cesi V., Cirinna' M., Lombardini S., Grassilli E., Bonatti S., Claudio P.P and B. Calabretta. BCR/ABL prevents c-Jun-mediated and proteasome-dependent TLS/FUS proteolysis through a PKC β -dependent pathway. *Mol. Cell. Biol.* 20(16): 6159-69, 2000. (#): co-corresponding author
25. Cirinna' M., R. Trotta, P. Salomoni, P. Kossev, M. Wasik, **D. Perrotti** and B. Calabretta.. Bcl-2 Expression Restores the Leukemogenic Potential of a BCR/ABL Mutant Defective in Transformation. *Blood*, 96(12): 3915-21, 2000.
26. **Perrotti D**[#], Cesi V, Trotta R., Guerzoni C, Santilli G., Campbell K., Iervolino A., Condorelli F., Gambacorti-Passerini C, Caligiuri MA. and B. Calabretta. BCR/ABL suppresses C/EBP α expression through the translation inhibitory activity of the hnRNP E2. *Nature Genetics*, 30: 48-58, 2002 (#): co-corresponding author
27. Iervolino A., G. Santilli, R. Trotta, C. Guerzoni, V. Cesi, A. Bergamaschi, C. Gambacorti-Passerini, B. Calabretta, and **D. Perrotti**. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. *Mol. Cell. Biol.* 22:2255-66, 2002.
28. **Perrotti D** and B. Calabretta. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: Role of the shuttling RNA binding proteins. *Oncogene*, 21:8577-83, 2002
29. Truong B-T. H., Lee Y-J, Lodie T.A., Park D. J., **Perrotti D.**, Watanabe N., Koeffler H. P., Nakajima H., Tenen D.G. and Kogan S.C. (2002) CCAAT/Enhancer Binding Proteins Repress the Leukemic Phenotype of Acute Myeloid Leukemia. *Blood*, 101:1141-1148. 2003
30. Trotta, R., T. Vignudelli, O. Candini, R. V. Intine, L. Pecorari, C. Guerzoni, G. Santilli, M.W. Byrom, S. Goldoni, L.P. Ford, M. A. Caligiuri, R.J. Maraia, **D. Perrotti***, and B. Calabretta. BCR/ABL activates mdm2 mRNA translation via the La antigen. *Cancer Cell*, 3:145-60.2003 (*) co-Corresponding Author.
31. Marcucci G., **D. Perrotti** and Caligiuri M.A. Understanding the molecular basis of Imatinib Mesylate therapy in CML and the related mechanisms of resistance. *Clin. Cancer Res.*, 9:1248-252, 2003.
32. Keeshan K., G. Santilli, F. Corradini, **D. Perrotti*** and B. Calabretta. The transcriptional activation function of C/EBP α is required for induction of granulocytic differentiation. *Blood*, 103:1267-75, 2003. (*) co-Corresponding Author.
33. **Perrotti D.** *, R. Trotta and B. Calabretta. Altered Translation: Possible mechanism for CML disease progression. *Cell Cycle*, 2: 177-180, 2003 (*) Corresponding Author.
34. **Perrotti D***, Marcucci G. and Caligiuri MA. Loss of C/EBP α and Favorable Prognosis of Acute Myeloid Leukemia: A biological paradox. *Journal of Clinical Oncology*, 22 (4), 2004. (*) Corresponding Author.

35. **Perrotti D*** and Calabretta B. Translational Regulation by the p210 BCR/ABL Oncoprotein. *Oncogene*, 23(18):3222-9, 2004 (*) : Corresponding Author.
36. Calabretta B and **Perrotti D**. The Biology of CML Blast Crisis. *Blood*, 103(11):4010-22, 2004.
37. Liu S, Shen T, Rush LJ, Klisovic MI, Ford JL, Yu J, Becknell B, Li Y, Liu C, Vukosavljevic T, Whitman SP, Chang K-S, Byrd JC, **Perrotti D**, Plass C and G. Marucci. RUNX1/MTG8 Associates With DNA Methyltransferase 1 to Disrupt Gene Expression In Acute Myeloid Leukemia. *Cancer Res*, 65:1277-84, 2005.
38. **Perrotti D***, Turturro F. and Neviani P. BCR/ABL, mRNA Translation and Apoptosis. *Cell Death Differ*. 2005, 6:534-40. (*) : Corresponding Author.
39. Marcucci G, Baldus C.D., Ruppert A.S., Radmacher M.D., Mrózek K., Whitman S.P., Klisovic M.I., Kolitz J.E., Edwards C.G., Vardiman J.W., Powell B.L., Baer M.R., Moore J.O., **Perrotti D**, Caligiuri M.A., Carroll A.J., Larson R.A., de la Chapelle A. and Bloomfield C.D. Overexpression of the ETS Transcription Factor *ERG* Predicts a Worse Outcome in Acute Myeloid Leukemia with Normal Karyotype: A Cancer and Leukemia Group B Study. *Journal of Clinical Oncology* 23:9234-42, 2005.
40. Neviani P., Santhanam R., Trotta R., Notari M., Blaser B.W., Liu S., Mao H, Chang JS, Galietta A, Uttam A, Roy D.C., Valtieri M., Bruner-Klisovic R., Caligiuri M.A., Bloomfield C.D., Marcucci G., and **D. Perrotti**. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. *Cancer Cell*.;8:355-68, 2005
- This article received printed and/or audio-visual (Fox News, MSNBC, ABC News in nearly 40 States within the US and AAAS radio news) press coverage from over 100 international (UK, Canadian, Italian, Russian, Spanish, South American, Indian, Chinese, Japanese, etc.) and national websites/journals, including Nature Reviews of Cancer, AAAS Science updates, Eurekalert, Reuters Health, Medpage Today, Medscape-WebMD, Federal Drug Administration news, Oncology Today, Oncolink, CMLhope, CML support, US Army-Dept of Defense Congressionally Directed Medical Research Program, AACI and American Society of Clinical Oncology. This article was also highlighted in the Annual Report of the Dept. of the Army-CDMRP-CML to the US Congress.*
41. Notari M., Neviani P., Santhanam R., Galietta A, Chang JS., Blaser B.W., Willis A.E., Roy D.C., Caligiuri M.A., Marcucci G. and **D. Perrotti**. A MAPK/hnRNP K pathway controls BCR/ABL oncogenic potential by regulating *c-myc* mRNA translation. *Blood*,107:2507-16, 2006
42. C. Guerzoni, M. Bardini, S. Mariani, G. Ferrari-Amorotti, M.L. Panno, P. Neviani, Y. Zhang, R. Martinez, **D. Perrotti**, and B. Calabretta: Inducible activation of C/EBP β , a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. *Blood*. 15;107(10):4080-9, 2006
43. S.-J. Chiu, S. Liu, **D. Perrotti**, G. Marcucci, and R.J. Lee Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor targeted liposomes, *J. Control. Release* 15;112(2):199-207, 2006
44. Lee Y-J, Jones L, Timchenko N.A., **Perrotti D.**, Tenen D.G., Kogan S.C. CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-*trans* retinoic acid in therapy but they differ in their anti-leukemic activities. *Blood* 108:2416-9, 2006
45. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, **Perrotti D**, Vardiman JW., Carroll AJ., Kolits JE., Larson RA, Bloomfield CD. *Cancer and Leukemia Group B (CALGB), Chicago, IL*. Adverse prognostic significance of KIT mutations in adult myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B (CALGB) study. *J. Clin. Oncol.*,24:3904-11, 2006

46. **Perrotti D.** and Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. *Br. J. Cancer*, 95:775-81, 2006
47. Becknell B., Hughes TL., Freud AG., Blaser BW, Yu J, Trotta R., Mao HC., Caligiuri de Jesús ML, Alghothani M, Benson, Jr. DM, Lehman A, Jarjoura D, **Perrotti D**, Bates MD, and Caligiuri MA. The Hlx homeobox transcription factor negatively regulates interferon- γ production in monokine-activated natural killer cells. *Blood* 109:2481-7, 2006
48. **Perrotti D.** and Neviani P. From mRNA metabolism to Cancer therapy: CML shows the way. *Clin. Cancer Res.* 13(6):1638-42, 2007
49. Liu Z., Liu, S., William B., **Perrotti D.**, Paschka P., Klisovic R., Byrd JC., Chan KK., G. Marcucci G. Characterization of In-Vitro and In-Vivo Hypomethylating Effect of Decitabine in Acute Myeloid Leukemia by a Rapid, Specific and Sensitive LC-MS/MS Method. *Nucl. Acid. Res.* 35(5):e31, 2007
50. Chen L., Shen R., Ye Y, Pu X-A, Liu X, Duan W-R, Wen J., Lasky LC, Nakano T, Heerema N, **Perrotti D**, Ozato K, Lin H-F, Barsky S, Gao J-X. Precancerous stem cells have the potential for both benign and malignant differentiation. *PLoS One.* 2:e293, 2007
51. Liu S, Klisovic R, Vukosavljevic T, Yu J, Paschka P., Huynh L., Pang X, Liu Z., Blum W., Chan KK, **Perrotti D** and G. Marcucci Targeting AML1/ETO-HDAC Repressor Complex: A Novel Mechanism Of Valproic Acid Mediated Gene Expression And Cellular Differentiation in AML1/ETO-positive Acute Myeloid Leukemia Cells. *J Pharmacol Exp Ther.* 321:953-60, 2007
52. Chang JS., Santhanam R., Trotta R., Neviani P., Eiring A., Briercheck E., Ronchetti M., Roy DC., Calabretta B., Caligiuri MA and **D. Perrotti**. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP E2-dependent suppression of C/EBP α -driven Myeloid Differentiation. . *Blood.* 2007 May 2; [Epub ahead of print]
53. Caligiuri MA, Briesewitz R, Yu J, Wang L, Wei M, Arnoczky KJ, Marburger TB, Wen J, **Perrotti D**, Bloomfield CD, Whitman SP. Novel c-CBL and CBL-B ubiquitin ligase mutations in human acute myeloid leukemia. *Blood.* 2007 May 2; [Epub ahead of print]
54. Galiotta A., Gunby R., Stano P., Carniti C., Bach A.i, Tartar C., Tucker P., Huang C., Colombo E., Pulford K., Puttini M., Piazza R., Ruchatz H., **Perrotti D***, and Gambacorti-Passerini C*. NPM/ALK Binds and Phosphorylates the RNA/DNA Binding Protein PSF in Anaplastic Large Cell Lymphoma. *Blood in press* 2007. (*: equal senior contribution)
55. Neviani P., Santhanam R., Oaks J., Eiring A., Notari M., Blaser BW., Liu S., Trotta R., Muthusamy N., Verrills, N., Gambacorti-Passerini C., Druker BJ., Cortes J., Marcucci G., Chen CS, Roy DC., Caligiuri MA., Bloomfield CD., Byrd J and **D. Perrotti**. FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL. *J Clin. Invest.* September 2007.
56. Trotta R., Dal Col J, Allard J., Neviani P., Santhanam R., Mao H., Becknell B, Yu J, Modi A., Blaser BW, **Perrotti D*** and Caligiuri MA*. In Vitro and In Vivo Evidence That the PP2A Inhibitor SET RegulatesIFN- γ Production in Monokine-Stimulated Natural Killer Cells. *J. Exp. Med in press* 2007 (*: equal senior contribution)
57. Koschmieder S., D'Alo F., Radomska H., Schöneich C., Chang JS., Konopleva M., Kobayashi S., Levantini E., Suh N., Santhanam, R., Di Ruscio A., Voso MT., Andreeff M., Sporn MB., **Perrotti D.**, Müller-

Tidow C., Serve H., and Tenen DG. CDDO induces granulomonocytic differentiation through translational upregulation of CEBP α . *Blood in press 2007*

58. Liu Q., Zhao X., Frizzera F, Ma Y., Santhanam R., Jarjoura D., Lehman A., **Perrotti D**, Chen C-S, Dalton JT, Muthusamy N. and Byrd JC. FTY720 Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma by a PP2A dependent mechanism. *Blood in press 2007*

Manuscripts submitted and in preparation

59. Eiring A., Oaks J., Neviani P., Chang JS., Notari M., Santhanam R., Willis W., Roy DC., Volinia S., Marcucci G., Caligiuri MA., Leone GW and **Perrotti D**. Identification of Novel Posttranscriptional Targets of BCR/ABL Oncoprotein by Ribonomics: Role of E2F3 in BCR/ABL leukemogenesis. *Manuscript submitted to Blood.*
60. Samanta AK, Wang Y, Cortes J, Kantarjian H, Champlin R, **Perrotti D** and Arlinghaus RB. Jak2 regulates Lyn tyrosine kinase through down-regulation of the SET/ PP2A/ Shp1 pathway in BCR-ABL+ imatinib-sensitive and resistant chronic myelogenous leukemia cells. *Blood submitted 2007*
61. Thomas EK., Cancelas JA., Chae H-D., Cox AD., Keller PJ., **Perrotti D.**, Neviani P., Druker BJ, Setchell KDR, Zheng Y., Harris EC. and D.A Williams. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. *Cancer Cell, resubmitted after revision, 2007*
62. Liu S., Liu Z., Xie Z., Pang J., Yu J., Lehmann E., Liu K., Sun J, Huynh L., Vukosavljevic T., Bruner-Klisovic R, Baiocchi R., Blum W., Porcu P., Garzon R., Byrd J., **Perrotti D.**, Caligiuri MA, Chan, K.K., Wu L-C., and Marcucci G. Interference of the Proteasome Inhibitor Bortezomib with Sp1-dependent DNA Methyltransferase Transcription: *Manuscript 2007 in preparation*
63. Marcucci G., Uttam A., Doarn M., Bloomfield C.D., de La Chapelle A. and **D Perrotti**. Mechanisms of Altered Myelopoiesis by the Oncogene FUS(TLS)-ERG of the t(16;21) Acute Myeloid Leukemias. *Manuscript in preparation 2007*
64. Auer H., Zuzan H, Norris A., Liu-Stratton Y. , Sen C., Carter D.E., Hegele R.A., Tiesman J.P., \ Torontali S.M., Grissom S.F., Tucker C.J., Göhlmann H.W.H, Van den Wyngaert I., Baldwin D., Straszewski G., Mohamed N., Newsom D., Knudtson K.L., Liyanarachchi S., **Perrotti D.**, Willey J.C., Kornacker K. Evaluation of Algorithms for Oligonucleotide Microarrays to Generate Comparable Results Across Laboratories. *Manuscript in Preparation 2007*

Book Chapters

1. Cimino, **D. Perrotti**, and A. Sacchi. " Gene Expression and Metastatic Phenotype in some murine carcinoma cells " *Biotechnology of Cell Regulation*, 4 (1991) 291-303. Editors: R. Verna and Y. Nishizuka. Raven Press, New York, NY.
2. Falcioni R., Cimino L., **Perrotti D.**, Rizzo M. G., and Sacchi A. " α 6/ β 4 Integrin in Lung Carcinoma" Cell adhesion molecules in cancer and Inflammation. Editors: A.A. Epenetos and M. Pignatelli. *Cell Adhesion & Communication Series*, ISSN 1023-7046 vol. 1, pg. 45-48. Harvard Academic Publishers, 1994.
3. B. Calabretta, **D. Perrotti**, T. Skorski and G. Zon. Experimenting in Animals. *UTET Encyclopedia*, 1995

4. B. Calabretta and **D. Perrotti***. Blastic Transformation of Chronic Myelogenous Leukemia: Does BCR/ABL orchestrate disease progression? "*Chronic Myelogenous Leukemia*" Edited by Deininger M. and Cortes J. Edit by Deininger M. and Cortes J. Taylor & Francis Publishers., Informa Healthcare ISBN: 9780849379550, Dec. 5th 2006.

Published Abstracts

1. **D. Perrotti**, L. Cimino, S. Ferrari and A. Sacchi. "Expression of cellular oncogenes in murine carcinoma cells with different metastatic potential". *Supplement to Journal of Cancer Research and Clinical Oncology*, vol. 116 pag. 174, 1990.
2. L. Cimino, R. Falcioni, M.G. Rizzo, **D. Perrotti**, and A. Sacchi. "Cloning of Beta 4 integrin subunit". *Cell Biology - International Reports*, vol. 14, Abstract Supplement Third European Congress of Cell Biology, 1990.
3. G. Tibursi, M.P. Gentileschi, R. Falcioni, L. Cimino, **D. Perrotti**, and A. Sacchi. "Metastatic phenotype: growth factor dependence and integrin expression". *Cell Biology - International Reports*, vol. 14, Abstract Supplement Third European Congress of Cell Biology, 1990.
4. G. Tibursi, M.P. Gentileschi, R. Falcioni, L. Cimino, **D. Perrotti**, and A. Sacchi. "Fenotipo metastatico: dipendenza da fattori di crescita ed espressione di integrine". *Tumori*, vol. 76 n°4, pag. 63, 1990.
5. Falcioni R., Tibursi G., Gentileschi M.P., Cimino L., **Perrotti D.**, and Sacchi A. "Dipendenza da fattori di crescita ed espressione di alcune integrine in cellule murine varianti per la capacità metastatica". *Atti del XI Convegno Nazionale della Associazione Italiana di Colture Cellulari*, pag.114, 1990.
6. L. Cimino, **D. Perrotti**, R. Falcioni and A. Sacchi. "Gene Expression and Metastatic Phenotype in some murine carcinoma cells " International Symposium on Biotechnology of Cell Regulation. University of Siena. Siena, Italy. June 20-22,1991. *Abstract Book*, pg. 31, # 20.
7. L. Cimino, **D. Perrotti**, R. Falcioni, M.G. Rizzo and A. Sacchi. "a6/b4 integrin expression and metastatic phenotype in 3LL cells" XI biennial meeting of the European Association for Cancer Research, Genoa, Italy 3-6 November 1991. *EJC*, Vol. 27 supplement 3 ,S30, # 4.016.
8. G. Citro, C. Cucco, **D. Perrotti**, I. D'Agnano, A. Sacchi, G. Zupi and B. Calabretta. "Inhibition of Leukemia cell proliferation by receptor mediated uptake of c-myb antisense oligodeoxynucleotides." *Third Annual Meeting of American Association for Cancer Research*. Vol. 33 - March 1992 San Diego - California - May 20-23 1992.
9. **D. Perrotti**, L. Cimino, M.G. Rizzo. S. Soddu and A. Sacchi. Metastatic phenotype and growth regulated gene expression. Prevenzione dell'Invasivita'. Progetto finalizzato A.C.R.O. I Riunione delle Unita' Operative. Chairman: P. M. Comoglio. Consiglio Nazionale delle Ricerche. Torino, June 11-12, 1992.
10. R. Falcioni, L. Cimino, **D. Perrotti**, S. J. Kennel, M.G. Rizzo and A. Sacchi. Metastatic phenotype and alpha6/beta4 integrin expression. Prevenzione dell'Invasivita'. Progetto finalizzato A.C.R.O. I Riunione delle Unita' Operative. Chairman: P. M. Comoglio. Consiglio Nazionale delle Ricerche. Torino, June 11-12, 1992.
11. G. Piaggio, A.Farina, **D. Perrotti**, A. Sacchi and C. Gaetano. "Isolation of the 5' flanking genomic sequences from the human cyclin B1 gene" *The Cell Cycle '93. Regulators, Targets and Clinical*

- Applications. XIIIth Washington International Spring Symposium - *Annual Symposium Volume of Abstract 1993*. May 10-14, 1993. Washington DC, USA.
12. G. Piaggio, A. Farina, **D. Perrotti**, A. Sacchi and C. Gaetano. "Isolation of the 5' flanking genomic sequences from the human cyclin B1 gene" *Atti del I Congresso Italiano di Oncologia Molecolare*. 5-8 Maggio 1993 Positano - Italy.
 13. L. Cimino, **D. Perrotti**, R. Falcioni, G. D'Agostino, S.J. Kennel and A. Sacchi. $\beta 4$ integrin subunit expression is down-regulated in low metastatic carcinoma variant. *Cancer detection and Prevention*. vol. 19 (1):117-118, 1995.
 14. **D. Perrotti**, P. Melotti, T. Skorski, I. Casella, C. Peshle and B. Calabretta. Overexpression of the Zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myc promoter activity. A.A.C.R. Special Conference. " *The Molecular Bases of Gene Transcription*" .
 15. R. Martinez, D. Venturelli, **D. Perrotti**, M. L. Veronese, K. Kastury, T. Druck, K. Huebner, and B. Calabretta. Gene structure, promoter activity and chromosomal location of the DR-nm23 gene. 6th International congress on cell biology and 36th American Society for Cell Biology Annual Meeting. San Francisco, California, USA, Dec 7-11, 1996. *Molecular biology of the cell*. Vol.7 (Suppl.):1723, 1996.
 16. **D. Perrotti**, T. Bellon, R. Trotta, R. Martinez, and B. Calabretta. A cell-proliferation dependent multiprotein complex NC-3A positively regulates the CD34 promoter via a TCATTT-containing element. 6th International congress on cell biology and 36th American Society for Cell Biology Annual Meeting. San Francisco, California, USA, Dec 7-11, 1996. *Molecular biology of the cell*. Vol.7 (Suppl.):2707, 1996.
 17. M. Nieborowska-Skorska, P. Wlodarski, **D. Perrotti**, R. Martinez, M. A. Wasik, B. Calabretta and T. Skorski. BCR/ABL oncogenic tyrosine kinase induces blastic transformation of p53-deficient bone marrow cells. 38th Annual Meeting American Society of Hematology. Orlando, Florida, USA. Dec 6-10, 1996. *Blood (Suppl.) 88(10):794, 1996*
 18. M. Nieborowska-Skorska, P. Wlodarski, **D. Perrotti**, M. Majewski, G. Zon, R. V. Iozzo, B. Calabretta and T. Skorski. Treatment of Philadelphia leukemia in SCID mice by combination of cyclophosphamide and BCR/ABL antisense oligodeoxynucleotides. . 38th Annual Meeting American Society of Hematology. Orlando, Florida, USA. Dec 6-10, 1996. *Blood (Suppl.) 88(10):2283, 1996*
 19. **D. Perrotti**, Martinez R., Trotta R., Salomoni P., Skorski T. and B. Calabretta. Regulation of BCR/ABL leukemic phenotype: role of a 68kDa RNA binding protein. 39th Annual Meeting American Society of Hematology. San Diego, CA, USA. Dec 5-9, 1997. *Blood (Suppl.) 90(10):787, 1997*
 20. M. Nieborowska-Skorska, A. Bellacosa, R. Martinez, M. Majewski, R. Trotta, P. Wlodarski, **D. Perrotti**, T. O. Chan, P.N. Tsichlis, B. Calabretta and Skorski T. Transformation of hematopoietic cells by BCR/ABL requires activation of PI-3K/Akt- depend pathway. 39th Annual Meeting American Society of Hematology. San Diego, CA, USA. Dec 5-9, 1997. *Blood (Suppl.) 90(10):787, 1997*
 21. Grassilli E., Salomoni P., **Perrotti D.**, Franceschi C. and B. Calabretta. Resistance to apoptosis in CTLL-2 cells overexpressing B-Myb is associated with B-Myb-dependent bcl-2 induction. Keystone Symposia on "Apoptosis (programmed cell death)", held in Breckenridge, CO, USA, April 6-11, 1999. *Abstract Book*.
 22. **D. Perrotti**, A. Iervolino, V. Cesi and B. Calabretta. BCR/ABL prevents c-Jun-mediated, proteasome-dependent and ubiquitin-independent TLS/FUS proteolysis through a PKC β II-dependent pathway. 41st

- Annual Meeting American Society of Hematology. New Orleans, LA, USA. Dec 3-7, 1999. *Blood (Suppl.)* 94(10): 2810, 1999
23. **Perrotti D.**, K. Campbell, R. Trotta, A. Iervolino, F. Condorelli, V. Cesi and B. Calabretta. Regulation of C/EBP α expression in normal and BCR/ABL-transformed hematopoietic cells. 42nd Annual Meeting American Society of Hematology. San Francisco, CA, USA. Dec 1-5, 2000. *Blood (Suppl.)* 96(11): 1517, 2000
 24. **Perrotti D.**, R. Trotta, A. V. Cesi, G. Santilli, C. Guerzoni, C. Gambacorti-Passerini, and B. Calabretta. Shuttling hnRNPs as Regulators of BCR/ABL Leukemogenic Potential. 43rd Annual Meeting American Society of Hematology. Orlando, FL, USA. Dec 7-11, 2001. *Blood (Suppl.)* 98(11): 142, 2001
 25. **Perrotti D.** and B. Calabretta. Genomics, Ribonomics and Proteomics: An Integrated Three Level Study To Characterize the Effect of BCR/ABL on mRNA Metabolism. 44th Annual Meeting American Society of Hematology. Philadelphia, PA, USA. Dec 6-10, 2002. *Blood (Suppl.)* 100(11): 4850, 2002
 26. Keeshan K., G. Santilli, B. Calabretta, **D. Perrotti**. Granulocytic Differentiation: The Scale Tilts towards C/EBP α -Induced Gene Transcription Rather Than Growth Suppression. 44th Annual Meeting American Society of Hematology. Philadelphia, PA, USA. Dec 6-10, 2002. *Blood (Suppl.)* 100(11): 4146, 2002
 27. Trotta R., T. Vignudelli, L. Pecorari, O. Candini, C. Guerzoni, G. Santilli, M. Byrom, S. Goldoni, L. Ford, M. A. Caligiuri, **D. Perrotti**, B. Calabretta. BCR/ABL Activates mdm2 mRNA Translation Via the La Antigen. 44th Annual Meeting American Society of Hematology. Philadelphia, PA, USA. Dec 6-10, 2002. *Blood (Suppl.)* 100(11): 2289, 2002.
 28. Neviani P., Notari M. and **D. Perrotti**. Identification of Novel Targets of BCR/ABL Oncoprotein by Ribonomics: Role of hnRNP A1 Shuttling Activity. 45th Annual Meeting American Society of Hematology. San Diego, CA, USA. Dec 6-9, 2003. *Blood (Suppl.)* 102(11): 421a, 2003.
 29. Notari M., Neviani P. and **D. Perrotti**. The Translational-Regulatory Activity of hnRNP K is required for BCR/ABL Leukemogenesis. 45th Annual Meeting American Society of Hematology. San Diego, CA, USA. Dec 6-9, 2003. *Blood (Suppl.)* 102(11): 652a, 2003.
 30. Uttam A., Auer H. and **D Perrotti**. Mechanisms of Altered Myelopoiesis by the Oncogene FUS(TLS)-ERG of the t(16;21) Acute Myeloid Leukemias. 45th Annual Meeting American Society of Hematology. San Diego, CA, USA. Dec 6-9, 2003. *Blood (Suppl.)* 102(11): 581a, 2003.
 31. Liu S., M. I. Klisovic, T. Shen, J. Yu, G. Dai, L. Huynh, T. Vukosavljevic, S. Whitman, **D. Perrotti**, G. Marcucci Promotes Gene Expression by Disrupting the DNA Binding of the AML1/ETO and HDAC1 Repressor Complex. 46th Annual Meeting American Society of Hematology. San Diego, CA, USA. Dec 4-7, 2004. *Blood (Suppl.)* 104(11): 4386, 2004.
 32. Neviani P., Santhanam R., Trotta R., Notari M., Uttam A., Blaser B.W., Liu S., Roy D.C., Caligiuri M.A., Bloomfield C. D., Marcucci G., and **D. Perrotti**. Activation of PP2A: A novel mechanism for a potential targeted therapy of blast crisis and imatinib-resistant chronic myelogenous leukemia. 96th Annual Meeting American Association for Cancer Research. April 16-20, 2005, Anaheim, CA. *Proceedings* 46: 1528, pg. 358, 2005.
 33. Liu S., Klisovic M.I., Shen T., Yu J., Dai G-W, Lenguyen H., Byrd J.C., **Perrotti D.**, Marcucci G. Molecular mechanism of gene expression and cell apoptosis mediated by hdac inhibitor valproic acid in acute myeloid leukemia cells. 96th Annual Meeting American Association for Cancer Research. April 16-20, 2005, Anaheim, CA. *Proceedings* 46: 1799, 2005.

34. Chang JK, Notari M., Marcucci G. and **Perrotti D.** BCR/ABL Post-Translationally Enhances hnRNP E2 Expression and Translation-Inhibitory Function through the Activation of ERK1/2 Mitogen-Activated Protein Kinases. 47th Annual Meeting American Society of Hematology. Dec. 9-13 Atlanta GA. *Blood (Suppl.)*, 106(11):4376, 2005.
35. Neviani P., Santhanam R., Trotta R., Notari M., Blaser B.W., Liu S., Mao H, Chang JS, Galietta A, Uttam A, Oaks J., Roy D.C., Valtieri M., Bruner-Klisovic R., Caligiuri M.A., Bloomfield C.D., Marcucci G., and **D. Perrotti.** ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML. 47th Annual Meeting American Society of Hematology. Dec. 9-13 Atlanta GA. *Blood (Suppl.)*, 106(11):1992, 2005.
36. Marcucci G., Baldus C.D., Ruppert A.S., Radmacher M.D., Mrózek K., Whitman S.P., Kolitz J.E., Edwards C.G., Vardiman J.W., Powell B.L., Baer M.R., Moore J.O., **Perrotti D.**, Caligiuri M.A., Carroll A.J., Larson R.A., de la Chapelle A., Bloomfield C.D. and Cancer and Leukemia Group B, CALGB, Chicago, IL. Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB). 47th Annual Meeting American Society of Hematology. Dec. 9-13 Atlanta GA. *Blood (Suppl.)*, 106(11):335, 2005.
37. Notari M., Neviani P., Santhanam R., Galietta A, Chang JS., Blaser B.W., Willis A.E., Roy D.C., Caligiuri M.A., Marcucci G. and **D. Perrotti.** A MAPK/hnRNP K pathway controls BCR/ABL oncogenic potential by regulating *c-myc* mRNA translation. 97th Annual Meeting American Association for Cancer Research. April 1-5, 2006. Washington DC. *Proceedings Abstract# 4283*, 2006.
38. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, **Perrotti D**, Larson RA, Bloomfield CD. *Cancer and Leukemia Group B (CALGB), Chicago, IL.* Mutations of *KIT* tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study. 2006 American Society of Clinical Oncology (ASCO) Meeting, Atlanta, GA, June 2 - 6, 2006. *Plenary Session Presentation.*
39. Chen L., Shen C, Duan W-R, Liu X., Wen J, Liu Y., Wang Y, Lasky L.C., **Perrotti D.**, Lin H-F, Gao J-X. Precancerous stem cells have the potential for both benign and malignant differentiation. FASEB-Experimental Biology 2006, Abstract 830.2. *FASEB J.* Minisymposium presentation "Insights from Pathobiology of Neoplasia for Better Prognosis" April 2006, San Francisco CA.
40. Chang JS, Santhanam R., Briercheck E., Eiring A., Trotta R., Notari M., Roy DC., Caligiuri MA., and **D. Perrotti.** Molecular and Pharmacologic Suppression of MAPK Activity Rescues Differentiation of BCR/ABL⁺ Myeloid Progenitors by Releasing C/EBP α from the Inhibitory Effect of hnRNP E2. 48th Annual Meeting American Society of Hematology, Dec. 9-12 Orlando FL. *Blood (Suppl)*, 108(11):2240, 2006.
41. Trotta R., Dal Col J, Allard J., Neviani P., Santhanam R., Mao H., Becknell B, Yu J, Modi A., Blaser BW, **Perrotti D.** and Caligiuri MA. In Vitro and In Vivo Evidence That the PP2A Inhibitor SET Regulates IFN- γ Production in Monokine-Stimulated Natural Killer Cells. 48th Annual Meeting American Society of Hematology, Dec. 9-12 Orlando FL. *Blood (Suppl)*, 108(11):928, 2006.
42. Santhanam R., Neviani P., Eiring A., Oaks J., Notari M., Blaser BW, Liu S., Trotta R., Muthusamy N., Marcucci G., Gambacorti C., Roy D.C., Caligiuri MA, Bloomfield CD, Chen C-S, Byrd JC and **D. Perrotti.** FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. 48th Annual Meeting American Society of Hematology, Dec. 9-12 Orlando FL. *Blood (Suppl)*, 108(11):288, 2006.)
43. Liu Q., Zhao X., Frizzera F, Ma Y., Santhanam R., **Perrotti D**, Chen C-S, Dalton JT, Byrd JC, and Muthusamy N. FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diolhydrochloride), Mediates

- Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma. 48th Annual Meeting American Society of Hematology, Dec. 9-12 Orlando FL. *Blood (Suppl)*, 108(11):2095, 2006.
44. Sun J, Liu S, Yu J, Wei M, Mao H, Ding H, Kearney J, Huynh L, Paschka P, Wang D, Klisovic R, **Perrotti D**, Chen C-S, Blum WG and Marcucci G. Characterization of HDACi OSU42 as a Novel Histone Deacetylase Inhibitor in AML Cell Lines. *Blood (Suppl)*, 108(11):1988, 2006.
 45. Liu S, Pang P, Yu J, Liu Z, Huynh L, Kearney J, Paschka P, Klisovic R, Baiocchi R, Blum WG, **Perrotti D**, and Marcucci G. Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF- κ B in AML1/ETO-Positive Cells. *Blood (Suppl)*, 108(11):4211, 2006.
 46. Neviani P., Santhanam R., Oaks J., Eiring A., Notari M., Blaser BW, Liu S., Trotta R., Muthusamy N., Gambacorti C., Druker BJ, Cortes J, Marcucci G., Chen C-S, Roy D.C., Caligiuri MA, Bloomfield CD, Byrd JC and **D. Perrotti**. FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients. 98th Annual Meeting American Association for Cancer Research. April 14-18, 2007. Los Angeles CA.
 47. Oaks et al. Jak2 and FTY ASH 2007
 48. Eiring et al. E2F3 ASH 2007
 49. Eiring et al. microRNA ASH 2007
 50. Williams Rac , ASH 2007
 51. Arlinghaus Jak2 ASH 2007

MEETINGS (posters and oral presentations) and Courses:

1. Italian Association of Clinical Oncology: "Lung Cancer: Biological and Clinical Features" Rome, Italy, Jan. 1990.
2. 1st Meeting "ANTISENSE OLIGODEOXYNUCLEOTIDE" Rome, Italy. May 11th, 1990.
3. 15th INTERNATIONAL CANCER CONGRESS (UICC) Presentation A2.096.06 - Session: Tumor Progression. Hamburg (Germany) 16-22 Aug. 1990.
4. ITALY - U.S.A.: Cancer Prevention and Biological Research Committee. Workshop on Biotechnology in Medicine "Tissue Engineering" Rome , 11 October 1990
5. DNA SYNTHESIZER CUSTOMER TRAINING COURSE: Model 391 PCR-Mate Oligosynthesizer, organized by Applied Biosystems, S.r.l., Milan, Italy. October 1990.
6. THE RNA WORLD: Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Accademia Nazionale dei Lincei , Rome (Italy), September 20, 1991.
7. 1st MEETING INVASION AND METASTASIS GROUP: Società Italiana di Cancerologia (S.I.C.), San Miniato, Pisa , 6-7 March 1992.
8. UNDERSTANDING THE CAUSES OF AGING CANCER: Prof. Bruce Ames (University of California) International Institute of Genetic and Biophysics (IIGB) -CNR. Naples, Italy. June 22-26, 1992.
9. A.A.C.R. Special Conference. " THE MOLECULAR BASES OF GENE TRANSCRIPTION" San Diego, CA. Dec 2-6, 1995.

10. 6th INTERNATIONAL CONGRESS ON CELL BIOLOGY AND 36th AMERICAN SOCIETY FOR CELL BIOLOGY ANNUAL MEETING. San Francisco, California, USA, Dec 7-11, 1996.
11. 39th ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY. San Diego, California, USA. Dec. 5-9, 1997.
12. 41st ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY. New Orleans, LA, USA. Dec 3-7, 1999.
13. 42nd ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, California, USA. Dec 1-5, 2000.
14. 43rd ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, Orlando, FL, USA. Dec 2-6, 2001.
15. 44th ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, Philadelphia, PA, USA. Dec 6-10. 2002.
16. 45th ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, CA, USA. Dec 5-9. 2003.
17. 4th Annual Division of Cancer Biology, National Cancer Institute, New Grantee Workshop. Rockville, Maryland. May 18-19, 2004.
18. 46th ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, CA, USA. Dec 4-7. 2004.
19. 7th Annual Meeting of The Ohio State University Comprehensive Cancer Center, March 11th 2005, Columbus, OH.
The presentation on "Therapeutic importance of PP2A activation in blast crisis and imatinib-resistant CML" by Neviani et al., ranked first in the competition among all of the presentations in the "Molecular Biology and Cancer Genetics" section.
20. 96th American Association for Cancer Research Annual Meeting, Anaheim, CA, USA. April 16-20 2005.
21. Third ESH International Conference on CHRONIC MYELOID LEUKAEMIA IN THE 21st CENTURY. Genoa, Italy November 2005.
22. Workshop on Myeloid Development. Section: Myeloid Malignancies. December 9th 2005, Atlanta GA.
23. 47th ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, Atlanta, GA, USA. Dec 9-14. 2005.
24. 8th Annual Meeting of The Ohio State University Comprehensive Cancer Center, March 2005, Columbus, OH.
25. 97th American Association for Cancer Research Annual Meeting, Washington DC, USA. April 1-5 2006.
26. FASEB Summer Research Conference on "Protein Phosphatases" July 15-20th, 2006. Snowmass Village, Colorado.
27. 48th ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, Orlando FL, USA. Dec 9-14. 2006
28. Road to a Cure: The CML Investigator's Meeting, Dec. 7-8 2006 Orlando, Florida. CDMRP, US Dept. of The Army – CML Research Program.
29. 1st Global CML Workshop – The Future, Bermuda, Dec. 14-17, 2006 (Session: Resistance to Imatinib)
30. 9^h Annual Meeting of The Ohio State University Comprehensive Cancer Center, February 2007, Columbus, OH.

31. 98th American Association for Cancer Research Annual Meeting, Los Angeles CA, USA. April 14-18, 2007.